Cost-effectiveness models, tailor-made for your market

As the backbone of any reimbursement submission, cost-effectiveness models must reflect perspectives and requirements, costs, and care pathways in each country where you are seeking reimbursement. We specialise in developing robust global models that underpin reimbursement strategy, withstand the test of time and can easily be adapted to local settings. We have decades of experience adapting global models for health technology assessment (HTA) agencies worldwide. Our models impress the toughest review groups with their rigour and transparency.

Early economic evaluations

In the early phases of drug or device development, a preliminary cost-effectiveness analysis is critical for strategic decision-making  about whether and how to continue product development. Our early economic models empower you to make important strategic decisions, set research priorities, and demonstrate the maximum value of your product.

Budget impact models

Budget impact models are an essential tool to demonstrate the affordability of your drug or device. We design user-friendly budget impact models for public and private payers in different countries.